Clinical trial NCT05954390: The Effect of LentinexHP® on Quality of Life in Stage IV Colorectal Cancer
Official title: The Effect of LentinexHP® on Quality of Life in Stage IV Colorectal Cancer: a Randomized, Parallel-group, Placebo-controlled Study
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Change in Mood
Change in Personality
Keywords: B-Glucan
Quality-of-Life
Colerectal Cancer
Lead sponsor: GlycaNova AS
Sponsor class: INDUSTRY
Collaborators: name: OPIS USA
First posted: 2023-07-20
Enrollment: 36
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a randomized, double-blind parallel-group, placebo-controlled study. that will last 40 weeks and will focus on Quality of Life.36 Subjects with stage IV metastatic colorectal cancer will be referred for study inclusion. Patients will be randomly assigned (1:1 ratio) to take 2 ml of LentinexHP or placebo orally twice a day (a total of 6 mg). Products will be dispensed to allow administration of the product for six weeks. Each bottle of LentinexHP or placebo contains 30 mL, which at 1.5 mg/mL will provide dosage for approximately five days. The patients will periodically complete the Functional Assessment of Cancer Therapy-Colorectal (FACT-C) Quality of Life (QoL) instrument, the short form 36 (SF-36), the Fatigue Symptom Inventory (FSI), and the QoL questionnaire used in the previous LentinexHP QoL study.

Detailed description: This is a randomized, double-blind parallel-group, placebo-controlled study. Subjects with stage IV metastatic colorectal cancer identified by the Principal Investigator or other qualified oncologists will be referred for potential study inclusion.

\* Baseline Visit (Week 1) After written informed consent and verification of eligibility criteria, patients will be randomly assigned (1:1 ratio) to take 2 ml of LentinexHP or placebo orally twice a day (a total of 6 mg). Products will be dispensed to allow administration of the product for six weeks. Each bottle of LentinexHP or placebo contains 30 mL, which at 1.5 mg/mL will provide dosage for approximately five days.

Patient demographics, blood chemistries, complete blood count (CBC), and vital signs, will be obtained from the patient's medical records and included as part of the study.

The patients will then complete the Functional Assessment of Cancer Therapy-Colorectal (FACT-C) Quality of Life (QoL) instrument, the short form 36 (SF-36), the Fatigue Symptom Inventory (FSI), and the QoL questionnaire used in the previous LentinexHP QoL s

* Visit 2 (Week 6) After six weeks, patients will be asked to return to the clinic and return used/unused bottles of LentinexHP or placebo for compliance evaluation. Patients will evaluate their QoL over the first six weeks of supplementation through the FACT-C, SF-36, FSI and the QoL questionnaire used in a prior LentinexHP study assessing QoL. Any self-perceived adverse events (AE) will be discussed with the patient. The Investigator will also review cancer treatments, vital signs and blood data (if available) to assess for any changes that might have occurred over the first six-week period.
* Visit 3 (Week 12) Patients will return to the clinic with their used/unused bottles of LentinexHP or placebo and again fill out the various QoL questionnaires. As in Visit 2, cancer treatments, blood data and vital signs obtained from medical records will be reviewed.

At this time patients will be given the option of taking LentinexHP free of charge for an additional 40 weeks. If they select that option, the sponsor will send them a 6-week supply of LentinexHP along with the four questionnaires to complete. After receiving the completed questionnaires for each 6-week period, another shipment of LentinexHP for the next 6 weeks will automatically be sent to the patients. Patients will be called every six weeks to enquire about survival, cancer treatments and any adverse events.

The duration of the study for each patient is 12 weeks, extending up to one year for patients opting to continue supplementation after the initial 12-week period.

Eligibility criteria: Inclusion Criteria:

* Signed written informed consent.
* Age 18 years or older.
* Male or female.
* Patients with stage IV metastatic colorectal cancer with less than three metastatic sites.
* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
* Patients starting on 1st or 2nd line chemotherapy with a 5-fluorouracil (5-FU) based regimen with or without biologics.

Exclusion Criteria:

* Patients with known or suspected hypersensitivity to any of the components of the test food supplement.
* Pregnant or breastfeeding.
* Treatment with an investigational drug within 5 half-lives or 30 days (whichever is longer) of randomization (COVID-19 drugs recommended by local regulatory authorities are permitted).
* Patients who in the opinion of the treating physician should not participate in this program.
* Prisoners.

Primary outcomes:
measure: Primary Objective: * The primary objective of the study is to explore the effect of LentinexHP versus placebo as an add-on non-drug therapy to improve QoL in patients with stage IVmetastatic colorectal cancer.
timeFrame: 12 Weeks
Secondary outcomes:
measure: Secondary Objective (Outcome 2)* A secondary objective of this study is to evaluate the patients' self-perception of their overall health.
timeFrame: 12 Weeks
Other outcomes:
measure: Secondary Objective (Outcome 3)* An additional secondary objective of this study is to evaluate the level of fatigue experienced by the patients during the study
timeFrame: 12 Weeks
Locations:
city: Haskovo
country: Bulgaria
facility: CLINECA EAD Hospital
Study officials:
affiliation: CLINECA EAD Hospital, Medical Oncology
name: Stoil Borchev, MD
role: PRINCIPAL_INVESTIGATOR
References: